THE INCIDENCE OF CD36 DEFICIENT MONOCYTE AND PLATELET AND ITS CORRELATION WITH DIABETES IN SOUTH KOREA
(Abstract release date: 05/19/16)
EHA Library. Kahng J. 06/09/16; 134969; PB2069
Prof. Jimin Kahng
Contributions
Contributions
Abstract
Abstract: PB2069
Type: Publication Only
Background
CD36, a synonymous term for platelet glycoprotein IV, GP (glycoprotein) IIIb, is an 88-kD glycoprotein that is expressed in such various cells as platelets, monocytes, macrophages, erythroblasts, capillary endothelial cells, adipocytes, epithelial cells in the kidney and cardiac myocytes. Hematologically, it is used as a representative antigen of platelets and monocytes in flow cytometric differential cell counting. Various reports prove the existence of racial variations with regard to CD36 deficiency: 0.3% in Caucasians, 3-11% in Japan, 0.5 % in Type 1 and 1.3 % in Type II for Chinese, and 0.3% of the U.S. population. And other studies show decreased insulin sensitivity and postprandial hypertriglyceridemia as the metabolic manifestations of CD36-deficient subjects. However, there has been no report on the nature of CD36 deficiency for Koreans.
Aims
The authors aim to find out CD36 deficiency incidence of South Korea and any potential correlations between diabetes patients by studying blood samples from diabetes patients, leukopenic samples, and normal samples.
Methods
We collected data from 757 individuals including 521 leukopenic patients, 105 diabetes patients, and 131 normal subjects at Seoul St. Mary’s Hospital, Seoul, Korea between August 2013 and March 2014. Routine CBC with WBC differential count with an automatic blood cell analyzer (DxH800) was performed in conjunction with analysis by flow cytometry by using Hematoflow with Cytodiff. The 5-color / 6-marker reagents (Cytodiff panel) were CD36-FITC, CD2-PE, CD294-PE, CD19-ECD, CD16-PC5, and CD45-PC7 antibodies. To confirm the platelets, CD41a-PE/CD36-FITC dual staining was added. To confirm the monocytes, CD11c-PE/CD36-FITC dual staining and peripheral blood smear slide reviews were used. We strictly adhered to the manufacturer’s manual for analysis: 100 uL of blood samples was mixed with 10 uL of Cytodiff reagent, and incubated for 20 min at room temperature. Lysing solution (Versalyse solution; Beckman Coulter) was used for 15 min to break down red blood cells. After washing, a flow cytometer (FC500) was used to collect 10,000 cells. The analysis software, self-gating and separating populations by automatic logic pathways, analyzed the Cytodiff results automatically. The gates were adjusted only in case of large debris contamination or incomplete separation of basophils and myeloblasts. Samples were all analyzed in duplicate.
Results
Of the 757 cases, 22 cases (2.91%) were either of type I (9 cases, 1.19%), or of type II (13 cases, 1.72%). Of 131 normal subjects, 4 cases (3.05%) were either of type I (1 case, 0.76%), or of type II (3 cases, 2.29%). Of 105 diabetes cases, 3 cases (2.86%) were of type II. And finally, of 521 leukopenic cases, 15 cases (2.88%) were either of type I (8 cases, 1.54%), or of type II (7 cases, 1.34%). Our t-tests showed no significant differences among the groups, and no correlation was found between diabetes and CD36 incidence, or between leucopenia and CD36 incidences (chi-square test and Fisher’s exact test), with the odd ratios of 0.97 and 0.98, respectively. No significant difference was found between the 22 cases and the remaining 735 cases in terms of sex, age, previous illness, hemoglobin level, WBC count, monocyte count, and platelet count.
Conclusion
The overall incidence of CD36 deficient monocytes and platelets based on 757 Korean subjects was 2.91%, manifesting no significant difference from the Japanese or Chinese studies, and no evident correlation with diabetes.
Session topic: E-poster
Keyword(s): Monocyte, Platelet
Type: Publication Only
Background
CD36, a synonymous term for platelet glycoprotein IV, GP (glycoprotein) IIIb, is an 88-kD glycoprotein that is expressed in such various cells as platelets, monocytes, macrophages, erythroblasts, capillary endothelial cells, adipocytes, epithelial cells in the kidney and cardiac myocytes. Hematologically, it is used as a representative antigen of platelets and monocytes in flow cytometric differential cell counting. Various reports prove the existence of racial variations with regard to CD36 deficiency: 0.3% in Caucasians, 3-11% in Japan, 0.5 % in Type 1 and 1.3 % in Type II for Chinese, and 0.3% of the U.S. population. And other studies show decreased insulin sensitivity and postprandial hypertriglyceridemia as the metabolic manifestations of CD36-deficient subjects. However, there has been no report on the nature of CD36 deficiency for Koreans.
Aims
The authors aim to find out CD36 deficiency incidence of South Korea and any potential correlations between diabetes patients by studying blood samples from diabetes patients, leukopenic samples, and normal samples.
Methods
We collected data from 757 individuals including 521 leukopenic patients, 105 diabetes patients, and 131 normal subjects at Seoul St. Mary’s Hospital, Seoul, Korea between August 2013 and March 2014. Routine CBC with WBC differential count with an automatic blood cell analyzer (DxH800) was performed in conjunction with analysis by flow cytometry by using Hematoflow with Cytodiff. The 5-color / 6-marker reagents (Cytodiff panel) were CD36-FITC, CD2-PE, CD294-PE, CD19-ECD, CD16-PC5, and CD45-PC7 antibodies. To confirm the platelets, CD41a-PE/CD36-FITC dual staining was added. To confirm the monocytes, CD11c-PE/CD36-FITC dual staining and peripheral blood smear slide reviews were used. We strictly adhered to the manufacturer’s manual for analysis: 100 uL of blood samples was mixed with 10 uL of Cytodiff reagent, and incubated for 20 min at room temperature. Lysing solution (Versalyse solution; Beckman Coulter) was used for 15 min to break down red blood cells. After washing, a flow cytometer (FC500) was used to collect 10,000 cells. The analysis software, self-gating and separating populations by automatic logic pathways, analyzed the Cytodiff results automatically. The gates were adjusted only in case of large debris contamination or incomplete separation of basophils and myeloblasts. Samples were all analyzed in duplicate.
Results
Of the 757 cases, 22 cases (2.91%) were either of type I (9 cases, 1.19%), or of type II (13 cases, 1.72%). Of 131 normal subjects, 4 cases (3.05%) were either of type I (1 case, 0.76%), or of type II (3 cases, 2.29%). Of 105 diabetes cases, 3 cases (2.86%) were of type II. And finally, of 521 leukopenic cases, 15 cases (2.88%) were either of type I (8 cases, 1.54%), or of type II (7 cases, 1.34%). Our t-tests showed no significant differences among the groups, and no correlation was found between diabetes and CD36 incidence, or between leucopenia and CD36 incidences (chi-square test and Fisher’s exact test), with the odd ratios of 0.97 and 0.98, respectively. No significant difference was found between the 22 cases and the remaining 735 cases in terms of sex, age, previous illness, hemoglobin level, WBC count, monocyte count, and platelet count.
Conclusion
The overall incidence of CD36 deficient monocytes and platelets based on 757 Korean subjects was 2.91%, manifesting no significant difference from the Japanese or Chinese studies, and no evident correlation with diabetes.
Session topic: E-poster
Keyword(s): Monocyte, Platelet
Abstract: PB2069
Type: Publication Only
Background
CD36, a synonymous term for platelet glycoprotein IV, GP (glycoprotein) IIIb, is an 88-kD glycoprotein that is expressed in such various cells as platelets, monocytes, macrophages, erythroblasts, capillary endothelial cells, adipocytes, epithelial cells in the kidney and cardiac myocytes. Hematologically, it is used as a representative antigen of platelets and monocytes in flow cytometric differential cell counting. Various reports prove the existence of racial variations with regard to CD36 deficiency: 0.3% in Caucasians, 3-11% in Japan, 0.5 % in Type 1 and 1.3 % in Type II for Chinese, and 0.3% of the U.S. population. And other studies show decreased insulin sensitivity and postprandial hypertriglyceridemia as the metabolic manifestations of CD36-deficient subjects. However, there has been no report on the nature of CD36 deficiency for Koreans.
Aims
The authors aim to find out CD36 deficiency incidence of South Korea and any potential correlations between diabetes patients by studying blood samples from diabetes patients, leukopenic samples, and normal samples.
Methods
We collected data from 757 individuals including 521 leukopenic patients, 105 diabetes patients, and 131 normal subjects at Seoul St. Mary’s Hospital, Seoul, Korea between August 2013 and March 2014. Routine CBC with WBC differential count with an automatic blood cell analyzer (DxH800) was performed in conjunction with analysis by flow cytometry by using Hematoflow with Cytodiff. The 5-color / 6-marker reagents (Cytodiff panel) were CD36-FITC, CD2-PE, CD294-PE, CD19-ECD, CD16-PC5, and CD45-PC7 antibodies. To confirm the platelets, CD41a-PE/CD36-FITC dual staining was added. To confirm the monocytes, CD11c-PE/CD36-FITC dual staining and peripheral blood smear slide reviews were used. We strictly adhered to the manufacturer’s manual for analysis: 100 uL of blood samples was mixed with 10 uL of Cytodiff reagent, and incubated for 20 min at room temperature. Lysing solution (Versalyse solution; Beckman Coulter) was used for 15 min to break down red blood cells. After washing, a flow cytometer (FC500) was used to collect 10,000 cells. The analysis software, self-gating and separating populations by automatic logic pathways, analyzed the Cytodiff results automatically. The gates were adjusted only in case of large debris contamination or incomplete separation of basophils and myeloblasts. Samples were all analyzed in duplicate.
Results
Of the 757 cases, 22 cases (2.91%) were either of type I (9 cases, 1.19%), or of type II (13 cases, 1.72%). Of 131 normal subjects, 4 cases (3.05%) were either of type I (1 case, 0.76%), or of type II (3 cases, 2.29%). Of 105 diabetes cases, 3 cases (2.86%) were of type II. And finally, of 521 leukopenic cases, 15 cases (2.88%) were either of type I (8 cases, 1.54%), or of type II (7 cases, 1.34%). Our t-tests showed no significant differences among the groups, and no correlation was found between diabetes and CD36 incidence, or between leucopenia and CD36 incidences (chi-square test and Fisher’s exact test), with the odd ratios of 0.97 and 0.98, respectively. No significant difference was found between the 22 cases and the remaining 735 cases in terms of sex, age, previous illness, hemoglobin level, WBC count, monocyte count, and platelet count.
Conclusion
The overall incidence of CD36 deficient monocytes and platelets based on 757 Korean subjects was 2.91%, manifesting no significant difference from the Japanese or Chinese studies, and no evident correlation with diabetes.
Session topic: E-poster
Keyword(s): Monocyte, Platelet
Type: Publication Only
Background
CD36, a synonymous term for platelet glycoprotein IV, GP (glycoprotein) IIIb, is an 88-kD glycoprotein that is expressed in such various cells as platelets, monocytes, macrophages, erythroblasts, capillary endothelial cells, adipocytes, epithelial cells in the kidney and cardiac myocytes. Hematologically, it is used as a representative antigen of platelets and monocytes in flow cytometric differential cell counting. Various reports prove the existence of racial variations with regard to CD36 deficiency: 0.3% in Caucasians, 3-11% in Japan, 0.5 % in Type 1 and 1.3 % in Type II for Chinese, and 0.3% of the U.S. population. And other studies show decreased insulin sensitivity and postprandial hypertriglyceridemia as the metabolic manifestations of CD36-deficient subjects. However, there has been no report on the nature of CD36 deficiency for Koreans.
Aims
The authors aim to find out CD36 deficiency incidence of South Korea and any potential correlations between diabetes patients by studying blood samples from diabetes patients, leukopenic samples, and normal samples.
Methods
We collected data from 757 individuals including 521 leukopenic patients, 105 diabetes patients, and 131 normal subjects at Seoul St. Mary’s Hospital, Seoul, Korea between August 2013 and March 2014. Routine CBC with WBC differential count with an automatic blood cell analyzer (DxH800) was performed in conjunction with analysis by flow cytometry by using Hematoflow with Cytodiff. The 5-color / 6-marker reagents (Cytodiff panel) were CD36-FITC, CD2-PE, CD294-PE, CD19-ECD, CD16-PC5, and CD45-PC7 antibodies. To confirm the platelets, CD41a-PE/CD36-FITC dual staining was added. To confirm the monocytes, CD11c-PE/CD36-FITC dual staining and peripheral blood smear slide reviews were used. We strictly adhered to the manufacturer’s manual for analysis: 100 uL of blood samples was mixed with 10 uL of Cytodiff reagent, and incubated for 20 min at room temperature. Lysing solution (Versalyse solution; Beckman Coulter) was used for 15 min to break down red blood cells. After washing, a flow cytometer (FC500) was used to collect 10,000 cells. The analysis software, self-gating and separating populations by automatic logic pathways, analyzed the Cytodiff results automatically. The gates were adjusted only in case of large debris contamination or incomplete separation of basophils and myeloblasts. Samples were all analyzed in duplicate.
Results
Of the 757 cases, 22 cases (2.91%) were either of type I (9 cases, 1.19%), or of type II (13 cases, 1.72%). Of 131 normal subjects, 4 cases (3.05%) were either of type I (1 case, 0.76%), or of type II (3 cases, 2.29%). Of 105 diabetes cases, 3 cases (2.86%) were of type II. And finally, of 521 leukopenic cases, 15 cases (2.88%) were either of type I (8 cases, 1.54%), or of type II (7 cases, 1.34%). Our t-tests showed no significant differences among the groups, and no correlation was found between diabetes and CD36 incidence, or between leucopenia and CD36 incidences (chi-square test and Fisher’s exact test), with the odd ratios of 0.97 and 0.98, respectively. No significant difference was found between the 22 cases and the remaining 735 cases in terms of sex, age, previous illness, hemoglobin level, WBC count, monocyte count, and platelet count.
Conclusion
The overall incidence of CD36 deficient monocytes and platelets based on 757 Korean subjects was 2.91%, manifesting no significant difference from the Japanese or Chinese studies, and no evident correlation with diabetes.
Session topic: E-poster
Keyword(s): Monocyte, Platelet
{{ help_message }}
{{filter}}